Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)
Opening soon Phase 3 NCT07680790
Run by Bristol-Myers Squibb · for 18 and older · All sexes
What this study is about
The purpose of this study is to evaluate izalontamab brengitecan (iza-bren) combined with osimertinib in participants with previously untreated, locally advanced or metastatic EGFR-mutant NSCLC, compared to osimertinib alone or osimertinib combined with platinum-based chemotherapy
Who can join (things the study team will check)
✅ You may be able to join if…
- Participants must have histologically or cytologically confirmed non-squamous NSCLC, newly diagnosed locally advanced (Stage IIIB/IIIC), metastatic (Stage IVA/IVB), or recurrent disease not amenable to curative surgery or definitive radiotherapy and requiring systemic treatment
- Participants must have documented EGFR-TKI-sensitizing mutation (exon 19 deletion or exon 21 L858R substitution)
- Participants must have measurable extracranial disease per RECIST v1.1 as assessed by the investigator
- Participants must have ECOG Performance Status 0-1
🚫 You may not be able to join if…
- Participants must not have unstable, symptomatic, or uncontrolled CNS metastases, including brain, leptomeningeal disease, and/or spinal cord compression
- Participants must not have history of ILD/pneumonitis requiring treatment with steroids (≥ Grade 2), or current or suspected ILD/pneumonitis
- Participants must not have clinically significant cardiac disease
- Other protocol-defined inclusion/exclusion criteria apply.
Where this trial is running
- Local Institution - 0212, Beverly Hills, California, United States
- Local Institution - 0504, Fullerton, California, United States
- Local Institution - 0357, La Jolla, California, United States
- Local Institution - 0520, Pueblo, Colorado, United States
- Local Institution - 0366, Orlando, Florida, United States
- Local Institution - 0519, Palm Bay, Florida, United States
- Local Institution - 0210, Honolulu, Hawaii, United States
- Local Institution - 0207, Ottawa, Illinois, United States
- Local Institution - 0503, Baltimore, Maryland, United States
- Local Institution - 0523, Silver Spring, Maryland, United States
- Local Institution - 0521, Edina, Minnesota, United States
- Local Institution - 0364, Saint Paul, Minnesota, United States
+ 168 more sites.
Who to contact
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com · 855-907-3286 · Clinical.Trials@bms.com
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT07680790.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.
Beacon is an information tool, not medical advice. Whether a trial is right for you is a decision for you, your doctor, and the study team. Trial details come from the official registry, ClinicalTrials.gov, and may change — always confirm with the study team. Beacon collects no data about you: this page has no cookies, no accounts, and no tracking.